Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Announces Crowdfunding Financing Campaign to Support Food Allergy Treatment Research
May 09, 2018 10:36 ET | Intrommune Therapeutics
New York, May 09, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics is pleased to announce the launch of a crowdfunding campaign on the Netcapital platform. This campaign supports the next steps of...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics to Present at Eighth Annual BioNJ BioPartnering Conference
April 24, 2018 09:27 ET | Intrommune Therapeutics
New York, April 24, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, announced today that it...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Announces Expansion of Advisory Board with Three Top Food Allergy Experts
June 14, 2016 07:30 ET | Intrommune Therapeutics
New York, June 14, 2016 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a specialty biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, today...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics to Present at 2016 BIO International Convention
June 06, 2016 07:55 ET | Intrommune Therapeutics
New York, June 06, 2016 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a specialty biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, today...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Announces Positive Results of Proof-of-Concept study of Oral Mucosal Immunotherapy (OMIT) Platform for the Treatment of Allergies
April 25, 2016 09:08 ET | Intrommune Therapeutics
Patient-friendly platform treats allergies while a patient brushes their teeth Oral mucosal route of administration demonstrated to be efficacious No gastrointestinal side effects...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Announces Issuance of U.S. Patent Covering Oral Mucosal Immunotherapy for Food Allergy
March 01, 2016 07:10 ET | Intrommune Therapeutics
New York, March 01, 2016 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a specialty biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, announced...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics to Present at New York Venture Capital Association 2016 Health & Bio Technology Summit
February 22, 2016 07:15 ET | Intrommune Therapeutics
New York, Feb. 22, 2016 (GLOBE NEWSWIRE) -- Intrommune Therapeutics,  a specialty biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, today...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics to Participate in Meetings with the Investment Community During the 34th Annual JP Morgan Healthcare Conference, January 11-14, 2016
December 29, 2015 09:41 ET | Intrommune Therapeutics
New York, NY, Dec. 29, 2015 (GLOBE NEWSWIRE) -- Intrommune Therapeutics (“Intrommune”), a New York City-based biotechnology company developing patient-friendly therapies for food allergy, today...